Asarina Pharma AB (publ) (ASAP.ST)
SEK 0.03
(-31.03%)
SEK 0.03
(-31.03%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.42 Million SEK | 96.36% |
| 2022 | 2.25 Million SEK | -75.55% |
| 2021 | 9.21 Million SEK | -41.24% |
| 2020 | 15.68 Million SEK | -23.19% |
| 2019 | 20.42 Million SEK | 111.21% |
| 2018 | 9.67 Million SEK | 221.58% |
| 2017 | 3 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | 4.42 Million SEK | 78.4% |
| 2023 Q2 | 2.48 Million SEK | 0.04% |
| 2023 Q1 | 2.48 Million SEK | 9.98% |
| 2023 FY | 4.42 Million SEK | 96.36% |
| 2023 Q4 | 4.42 Million SEK | 0.05% |
| 2022 Q4 | 2.25 Million SEK | 0.0% |
| 2022 FY | 2.25 Million SEK | -75.55% |
| 2022 Q3 | 2.25 Million SEK | 20.72% |
| 2022 Q2 | 1.86 Million SEK | -75.6% |
| 2022 Q1 | 7.65 Million SEK | -16.93% |
| 2021 FY | 9.21 Million SEK | -41.24% |
| 2021 Q4 | 9.21 Million SEK | -12.34% |
| 2021 Q3 | 10.51 Million SEK | -19.49% |
| 2021 Q1 | 5.28 Million SEK | -66.34% |
| 2021 Q2 | 13.06 Million SEK | 147.3% |
| 2020 Q3 | 5.72 Million SEK | 28.94% |
| 2020 Q1 | 11.29 Million SEK | -44.7% |
| 2020 FY | 15.68 Million SEK | -23.19% |
| 2020 Q4 | 15.68 Million SEK | 174.25% |
| 2020 Q2 | 4.43 Million SEK | -60.73% |
| 2019 Q1 | 7.58 Million SEK | -21.6% |
| 2019 Q2 | 8.33 Million SEK | 9.88% |
| 2019 FY | 20.42 Million SEK | 111.21% |
| 2019 Q4 | 20.42 Million SEK | 32.77% |
| 2019 Q3 | 15.38 Million SEK | 84.67% |
| 2018 Q2 | 2.99 Million SEK | 0.0% |
| 2018 FY | 9.67 Million SEK | 221.58% |
| 2018 Q1 | - SEK | -100.0% |
| 2018 Q4 | 9.67 Million SEK | 71.45% |
| 2018 Q3 | 5.64 Million SEK | 88.25% |
| 2017 Q4 | 3 Million SEK | 0.0% |
| 2017 FY | 3 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.717% |
| AcouSort AB (publ) | 10.37 Million SEK | 57.352% |
| Active Biotech AB (publ) | 13.4 Million SEK | 66.97% |
| Alzinova AB (publ) | 9.33 Million SEK | 52.567% |
| Amniotics AB (publ) | 10.54 Million SEK | 58.035% |
| BioArctic AB (publ) | 139.5 Million SEK | 96.827% |
| Camurus AB (publ) | 414.81 Million SEK | 98.933% |
| Cantargia AB (publ) | 54.97 Million SEK | 91.948% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -15.32% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 67.861% |
| Genovis AB (publ.) | 98.04 Million SEK | 95.486% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 76.068% |
| Mendus AB (publ) | 51.22 Million SEK | 91.36% |
| Kancera AB (publ) | 17.97 Million SEK | 75.381% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 61.743% |
| LIDDS AB (publ) | 3.75 Million SEK | -17.838% |
| Lipum AB (publ) | 7.53 Million SEK | 41.284% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | 14.192% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 96.43% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -87.622% |
| NextCell Pharma AB | 13.68 Million SEK | 67.668% |
| OncoZenge AB (publ) | 1.69 Million SEK | -160.506% |
| Saniona AB (publ) | 86.08 Million SEK | 94.858% |
| Simris Alg AB (publ) | 148.93 Million SEK | 97.028% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 89.168% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 99.082% |
| Xintela AB (publ) | 14.01 Million SEK | 68.42% |
| Ziccum AB (publ) | 6.38 Million SEK | 30.714% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 76.905% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 93.84% |
| CombiGene AB (publ) | 4.15 Million SEK | -6.497% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 93.777% |
| Intervacc AB (publ) | 21.68 Million SEK | 79.585% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 95.848% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 87.209% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 83.428% |
| Corline Biomedical AB | 6.78 Million SEK | 34.806% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 92.786% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 72.538% |
| Aptahem AB (publ) | 8.99 Million SEK | 50.81% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 90.416% |
| Fluicell AB (publ) | 8.91 Million SEK | 50.353% |
| Biovica International AB (publ) | 34.76 Million SEK | 87.27% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 62.067% |
| Abliva AB (publ) | 16.78 Million SEK | 73.625% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 97.938% |
| 2cureX AB (publ) | 2.93 Million SEK | -50.801% |
| I-Tech AB | 16.2 Million SEK | 72.687% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.627% |
| Cyxone AB (publ) | 4.69 Million SEK | 5.709% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 66.792% |
| Biosergen AB | 5.08 Million SEK | 12.96% |
| Nanologica AB (publ) | 79.32 Million SEK | 94.421% |
| SynAct Pharma AB | 51.83 Million SEK | 91.461% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | 44.32% |
| BioInvent International AB (publ) | 90.45 Million SEK | 95.107% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | 14.802% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 97.563% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -146.711% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 65.27% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | 39.036% |